Research use only. Nothing on this page is medical advice.
DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide first isolated from rabbits in 1977. Two small insomnia trials from 1987 disagree, it did not change cortisol in people, and it is not FDA-approved.
- Sleep: one 1987 trial found little clinical benefit and another reported better sleep, both in small groups (1, 2).
- Cortisol (the stress hormone): no effect in healthy men (3).
- Law: not approved, and an FDA advisory committee voted against listing it for compounding in July 2026 (4).
- Buying: three sellers below post lot reports from named labs.
Where to buy DSIP: 3 sellers with lot reports
Amino Club
DSIP 5 mg · from $29.99
- Lot report on the product page from ILS Laboratories, an independent ISO/IEC 17025 lab
- Lot DSP0001: 99.45% purity by HPLC, 5.22 mg measured against 5 mg labeled
- Free standard shipping over $100
Elite Edge Biotech
DSIP 5 mg · $20.00
- Batch report from MZ Biolabs (Tucson, AZ): 98.14% purity by HPLC-UV-MS
- Identity confirmed by mass spectrometry: 848.31 daltons (Da) measured, 848.33 expected
- US shipping, free over $200
Platinum Biolabs
DSIP 10 mg · $51.00 after 25% off ($68.00 list)
- Purity report from Horizon Analytical (UPLC-MS): 99.47%, 10.11 mg measured against 10 mg labeled
- A separate endotoxin test report is posted on the product page
- 30-day returns, ships from Houston, TX
Each of these sellers posts a lot report with purity data from a named lab. HPLC measures purity, and mass spectrometry confirms identity. Also stocked: SwissChems DSIP 2 mg at $24.95 per vial. Ask any seller for the report that matches your lot number, and compare more in best peptide vendors.
What is DSIP?
DSIP is the peptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, about 849 Da in weight. Brain infusion in rabbits increased delta (slow-wave) and spindle brain activity (5). FDA lists it as emideltide (DSIP) (6). It is not approved for any use, and its human evidence is a handful of small studies from the 1980s and 1990s.
What do the human studies show?
How to read the table. Benefit reported: the authors reported improvement. No clear benefit, No control group: results too weak to rely on. No effect: no change from placebo.
| Study | What it found | Main limit |
|---|---|---|
| Insomnia, 4 nights, crossover (1987) | No clear benefitEach person got both DSIP and placebo. Total sleep time and NREM (non-dream) sleep rose, mainly stage 2, but the same differences existed at baseline. Deep slow-wave sleep and REM (dream) sleep did not change. The authors called the improvement of little clinical significance (1) | Small, given through a vein (IV) in a clinic |
| Severe insomnia, 14 people, 7 nights (1987) | Benefit reportedNight sleep improved, sleep efficiency reached the level of normal controls, and daytime alertness and performance rose (2) | One author, 14 people, never repeated |
| Cortisol, healthy men (1995) | No effectResponses of ACTH (a pituitary stress hormone) and cortisol were almost identical to placebo in 5 men per condition, and unchanged in a meal test with 10 men (3) | Tiny groups of healthy men |
| Opiate and alcohol withdrawal, 107 inpatients (1984) | No control groupSymptoms disappeared or improved markedly in 97% of opiate and 87% of alcohol patients who could be evaluated. A few patients had headaches (7) | No placebo group is mentioned. 13% to 22% could not be evaluated |
Nobody has repeated either sleep trial with modern methods, and neither tells you what a nasal spray or injection sold online does. No DSIP trial is registered on ClinicalTrials.gov.
Is there a DSIP protocol?
No validated human protocol exists. The studies above gave DSIP by IV or injection in clinics. This page does not list doses, cycles or stacks.
Is DSIP FDA-approved or legal?
- Not approved. FDA says compounded DSIP may pose an immunogenicity risk (an immune reaction) and that it has found no safety information for the proposed route (6).
- July 2026 vote. FDA’s compounding advisory committee voted 6 for and 7 against, with 1 abstention, on emideltide. It backed six other peptides. FDA staff opposed all seven (4, 8).
- HHS policy. The 28 October 2026 interim policy names six peptides. DSIP is not one of them (9).
Is DSIP safe?
Nobody knows. FDA says it lacks the information to know whether compounded DSIP would cause harm (6). In the 1984 withdrawal report, a few patients had headaches (7).
How do you check a DSIP vial?
- Match the lot number on your vial to a lab report.
- Check for a named lab you can look up, as in the Elite Edge report from MZ Biolabs.
- Look for identity data from mass spectrometry alongside the purity number. Elite Edge lists 848.31 Da measured against 848.33 Da expected.
- Check for an endotoxin or sterility result. Platinum Biolabs posts a separate endotoxin report.
- Walk away if there is no report, the price is far below other sellers, or the seller has an FDA warning letter.
Our COA guide shows how to read each line, and peptide scams to avoid lists sellers to skip. For another peptide studied for circadian rhythm, read our epitalon guide.
DSIP FAQ
What is DSIP?
DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide first isolated from rabbits in 1977. It increased slow-wave brain activity in rabbits. It is not approved for any use, and human evidence is limited to small studies from the 1980s and 1990s.
Is DSIP the same as emideltide?
Yes. FDA lists the peptide as emideltide (DSIP) on its compounding risk page.
Does DSIP work for sleep?
Not clearly. A 1987 crossover trial found little clinical benefit, while a 1987 study of 14 severe insomniacs reported better night sleep and daytime performance. Both were small and neither has been repeated.
Is there a DSIP protocol?
No validated human protocol exists. The human studies gave DSIP by IV or injection in clinics, and this page does not list doses, cycles or stacks.
Does DSIP lower cortisol?
No human study supports it. In healthy men, ACTH and cortisol responses to DSIP were almost identical to placebo.
Is DSIP FDA-approved?
No. FDA lists it as a compounding risk, and its advisory committee voted 6 for and 7 against, with 1 abstention, on adding it to the 503A bulks list in July 2026. The HHS policy of 28 October 2026 does not cover it.
Is DSIP safe?
Nobody knows. FDA says it lacks the information to know whether compounded DSIP would cause harm, and it flags an immunogenicity risk for some routes.
Where can you find third-party tested DSIP?
Amino Club, Elite Edge Biotech and Platinum Biolabs each post a lot report with purity data from a named lab. Match the lot number on your vial to the report, and use our COA guide to read it.
Sources
Show references (9)Hide references
- Monti JM, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res 1987. Source
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol 1987. Source
- Spath-Schwalbe E, et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology 1995. Source
- The FDA Law Blog. The PEPTIDE-L wave rolls on: PCAC adds two more bulk drug substances for the 503A list. July 2026. Source
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA 1977. Source
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (category 2). Page current as of 22 April 2026. Source
- Dick P, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol 1984. Source
- Fierce Pharma. Peptide adcomm day 2: emideltide voted down in panel’s first pushback. July 2026. Source
- BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. 28 October 2026. Source